BioNano Genomics Inc BNGO shares traded higher by 6.9% to $4.41 after the company reported better-than-expected first-quarter sales results.
Bionano Genomics reported quarterly sales of $3.2 million, which beat the analyst consensus estimate of $2.9 million.
See also: How to Buy Bionano Genomics Inc. (BNGO) Stock
Bionano Genomics is a life sciences instrumentation company in the genome analysis space. It's engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.